Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells

Experimental Cell Research

Volumn 319, Issue 4, 2013, Pages 566-574

  Pouliot, Lynn M ^a,b   Shen, Ding Wu ^b   Suzuki, Toshihiro ^c   Hall, Matthew D ^b   Gottesman, Michael M ^b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Cisplatin; Drug resistance; Drug selection; MicroRNA

Indexed keywords

CISPLATIN; MICRORNA; MICRORNA 181; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEAD BOX PROTEIN; DICER1 PROTEIN, HUMAN; RIBONUCLEASE III; RNA BINDING PROTEIN; SMALL INTERFERING RNA; TRANS ACTIVATION RESPONSIVE RNA BINDING PROTEIN; TRANS-ACTIVATION RESPONSIVE RNA-BINDING PROTEIN;

ADENOCARCINOMA; ARTICLE; BIOSYNTHESIS; CANCER CELL; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HELA CELL; PHYSIOLOGY; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DEAD-BOX RNA HELICASES; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MICRORNAS; RIBONUCLEASE III; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TRANSFECTION; UTERINE CERVICAL NEOPLASMS;

MLCS; MLOWN;

EID: 84875548414     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.10.012     Document Type: Article

References (38)

1. Eastman A. The mechanism of action of cisplatin: from adducts to apoptosis. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug 1999, 111-134. Verlag Helvetica Chimica Acta, Zurich, Switzerland. B. Lippert (Ed.).
2. Gottesman M.M., Hall M.D., Liang X.J., Shen D.W. Resistance to cisplatin results from multiple mechanisms in cancer cells. Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy 2009, 83-88. Humana Press, New York. A. Bonetti, F.M. Muggia, R. Leone, S.B. Howell (Eds.).
3. Hall M.D., Handley M.D., Gottesman M.M. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol. Sci. 2009, 30:546-556.
4. Hall M.D., Okabe M., Shen D.W., Liang X.J., Gottesman M.M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu. Rev. Pharmacol. Toxicol. 2008, 48:495-535.
5. Shen D.W., Pouliot L.M., Hall M.D., Gottesman M.M. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 2011, 64:706-721.
6. Shen D., Pastan I., Gottesman M.M. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res. 1998, 58:268-275.
7. Basu A., Krishnamurthy S. Cellular responses to cisplatin-induced DNA damage. J. Nucleic Acids 2010, 1-16.
8. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J. Biol. Chem. 1994, 269:787-790.
9. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
10. Bushati N., Cohen S.M. microRNA functions. Annu. Rev. Cell. Dev. Biol. 2007, 23:175-205.
11. Kosik K.S. MicroRNAs and cellular phenotypy. Cell 2010, 143. 21-26.
12. Wienholds E., Plasterk R.H. MicroRNA function in animal development. FEBS Lett. 2005, 579:5911-5922.
13. Ma J., Dong C., Ji C. MicroRNA and drug resistance. Cancer Gene Ther. 2010, 17:523-531.
14. Sorrentino A., Liu C.G., Addario A., Peschle C., Scambia G., Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol. Oncol. 2008, 111:478-486.
15. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10:704-714.
16. Ferracin M., Pedriali M., Veronese A., Zagatti B., Gafa R., Magri E., Lunardi M., Munerato G., Querzoli G., Maestri I., Ulazzi L., Nenci I., Croce C.M., Lanza G., Querzoli P., Negrini M. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J. Pathol. 2011, 225:43-53.
17. Slaby O., Lakomy R., Fadrus P., Hrstka R., Kren L., Lzicarova E., Smrcka M., Svoboda M., Dolezalova H., Novakova J., Valik D., Vyzula R., Michalek J. MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma 2010, 57:264-269.
18. Yang C.C., Hung P.S., Wang P.W., Liu C.J., Chu T.H., Cheng H.W., Lin S.C. miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. J. Oral Pathol. Med. 2011, 40:397-404.
19. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., Wojcik S.E., Aqeilan R.I., Zupo S., Dono M., Rassenti L., Alder H., Volinia S., Liu C.G., Kipps T.J., Negrini M., Croce C.M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 2005, 102:13944-13949.
20. Ouyang Y.B., Lu Y., Yue S., Giffard R.G. miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes. Mitochondrion 2011, 12:213-219.
21. Pekarsky Y., Santanam U., Cimmino A., Palamarchuk A., Efanov A., Maximov V., Volinia S., Alder H., Liu C.G., Rassenti L., Calin G.A., Hagan J.P., Kipps T., Croce C.M. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006, 66:11590-11593.
22. Cichocki F., Felices M., McCullar V., Presnell S.R., Al-Attar A., Lutz C.T., Miller J.S. Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling. J. Immunol. 2011, 187:6171-6175.
23. Liu G., Min H., Yue S., Chen C.Z. Pre-miRNA loop nucleotides control the distinct activities of mir-181a-1 and mir-181c in early T cell development. PLoS One 2008, 3:e3592.
24. Naguibneva I., Ameyar-Zazoua M., Polesskaya A., Ait-Si-Ali S., Groisman R., Souidi M., Cuvellier S., Harel-Bellan A. The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation. Nat. Cell Biol. 2006, 8:278-284.
25. Kim C.H., Kim H.K., Rettig R.L., Kim J., Lee E.T., Aprelikova O., Choi I.J., Munroe D.J., Green J.E. miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med. Genomics 2011, 4:79.
26. Liang X.J., Shen D.W., Garfield S., Gottesman M.M. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res. 2003, 63:5909-5916.
27. Shen D.W., Liang X.J., Gawinowicz M.A., Gottesman M.M. Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines. Mol. Pharmacol. 2004, 66:789-793.
28. Shen D.W., Su A., Liang X.J., Pai-Panandiker A., Gottesman M.M. Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br. J. Cancer 2004, 91:270-276.
29. Fujiwara Y., Sugimoto Y., Kasahara K., Bungo M., Yamakido M., Tew K.D., Saijo N. Determinants of drug response in a cisplatin-resistant human lung cancer cell line. Jpn. J. Cancer Res. 1990, 81:527-535.
30. Ohmori T., Morikage T., Sugimoto Y., Fujiwara Y., Kasahara K., Nishio K., Ohta S., Sasaki Y., Takahashi T., Saijo N. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP). Jpn. J. Cancer Res. 1993, 84:83-92.
31. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001, 25:402-408.
32. Christensen H.S., Daher A., Soye K.J., Frankel L.B., Alexander M.R., Laine S., Bannwarth S., Ong C.L., Chung S.W., Campbell S.M., Purcell D.F., Gatignol A. Small interfering RNAs against the TAR RNA binding protein, TRBP, a Dicer cofactor, inhibit human immunodeficiency virus type 1 long terminal repeat expression and viral production. J. Virol. 2007, 81:5121-5131.
33. Bu Y., Lu C., Bian C., Wang J., Li J., Zhang B., Li Z., Brewer G., Zhao R.C. Knockdown of Dicer in MCF-7 human breast carcinoma cells results in G1 arrest and increased sensitivity to cisplatin. Oncol. Rep. 2009, 21:13-17.
34. Shen D.W., Gottesman M.M. RAB8 Enhances TMEM205-mediated cisplatin resistance. Pharm. Res. 2012, 29:643-650.
35. Shen D.W., Ma J., Okabe M., Zhang G., Xia D., Gottesman M.M. Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. J. Cell Physiol. 2010, 225:822-828.
36. Galluzzi L., Morselli E., Vitale I., Kepp O., Senovilla L., Criollo A., Servant N., Paccard C., Hupe P., Robert T., Ripoche H., Lazar V., Harel-Bellan A., Dessen P., Barillot E., Kroemer G. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2010, 70:1793-1803.
37. Zhu W., Shan X., Wang T., Shu Y., Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int. J. Cancer 2010, 127:2520-2529.
38. Pouliot L.M., Chen Y.C., Bai J., Guha R., Martin S.E., Gottesman M.M., Hall M.D. Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res 2012, 72:5945-5955.